5 Top Stocks Driven by Strong Relative Price Strength Now
PARR, AU, GMED, ALNT and SNDK emerge as top picks after posting gains, rising estimates and sustained relative price outperformance.
Globus Medical ( GMED ) is an Incredible Growth Stock: 3 Reasons Why
Globus Medical (GMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why Globus Medical ( GMED ) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Force Feedback the Next Big Catalyst for ISRG's da Vinci Sales?
Intuitive Surgical's new force-feedback upgrades for da Vinci 5 could spark its next adoption wave as early clinical evidence strengthens.
Globus Medical ( GMED ) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Nasdaq Tumbles Over 100 Points; US Consumer Sentiment Falls In November - Fox Factory Holding ( NASDAQ:FOXF ) , AirSculpt Technologies ( NASDAQ:AIRS )
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling more than 100 points on Friday. The Dow traded up 0.06% to 46,941.27 while the NASDAQ fell 0.45% to 22,951.03. The S&P 500 also fell, dropping, 0.04% to 6,717.41. In trading on Friday, communication services ...
Dropbox, Globus Medical, Expedia, Genpact And Other Big Stocks Moving Higher On Friday - Akamai Technologies ( NASDAQ:AKAM ) , Affirm Holdings ( NASDAQ:AFRM )
U.S. stocks were lower, with the Nasdaq Composite falling more than 1% on Friday. Shares of Dropbox Inc ( NASDAQ:DBX ) rose 8.3% to $31.05 following upbeat quarterly earnings. Dropbox reported quarterly earnings of 74 cents per share which beat the analyst consensus estimate of 65 cents per ...
This Expedia Group Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday - Globus Medical ( NYSE:GMED ) , Expedia Group ( NASDAQ:EXPE )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Globus Medical ( GMED ) Tops Q3 Earnings and Revenue Estimates
Globus Medical (GMED) delivered earnings and revenue surprises of +49.37% and +4.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
DENTSPLY SIRONA ( XRAY ) Q3 2025 Earnings Transcript
Image source: The Motley Fool.Thursday, November 6, 2025 at 8:30 a.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
CVRx ( CVRX ) Reports Q3 Loss, Beats Revenue Estimates
CVRx (CVRX) delivered earnings and revenue surprises of +2.00% and +3.33%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Rigetti Computing to Post Q3 Earnings: What's in Store for the Stock?
RGTI's Q3 results are likely to gain from U.S. funding clarity, new contracts and gains from its next-gen quantum system.
Globus Medical ( GMED ) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Beyond analysts' top-and-bottom-line estimates for Globus Medical (GMED), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.
Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
• Marks Aclarion's first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgery • Experiencing strong commercial traction in UK as first market worldwide with private insurers covering Nociscan • Nociscan reimbursed ...
Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion - Aclarion ( NASDAQ:ACONW ) , Aclarion ( NASDAQ:ACON )
Marks Aclarion's first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgery Experiencing strong commercial traction in UK as first market worldwide with private insurers covering Nociscan
NeuroPace, Inc. ( NPCE ) Reports Q3 Loss, Tops Revenue Estimates
NeuroPace (NPCE) delivered earnings and revenue surprises of +45.00% and +11.38%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
DENTSPLY SIRONA to Post Q3 Earnings: What's in Store for the Stock?
Dentsply Sirona's Q3 results may reveal ongoing softness in U.S. demand and orthodontic segments despite steady cost control.
Solventum to Post Q3 Earnings: Is a Beat Likely for the Stock?
Solventum's Q3 results may reflect softer sales and tariff impacts, though pricing discipline and core growth drivers likely aided margins.
Will Strong Segmental Performance Drive MCK's Top Line in Q2?
McKesson's Q2 results may show steadier growth as strong U.S. pharmaceutical and RxTS momentum drive its expanding top line.
Prescription for Beats: 3 Healthcare Stocks Set to Outperform in Q3
Humana, Cencora and Globus Medical are poised to outshine in the September quarter, driven by strong demand, innovation and volume growth.
Globus Medical ( GMED ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical ( GMED ) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Ekso Bionics ( EKSO ) Reports Q3 Loss, Beats Revenue Estimates
Ekso Bionics (EKSO) delivered earnings and revenue surprises of +45.45% and +8.11%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Baxter Q3 Preview: Can Core Segments Deliver Another Solid Quarter?
Baxter's Q3 results are expected to show steady revenue growth led by Advanced Surgery and Drug Compounding, though IV fluid and anesthesia softness may weigh on EPS.
Will SYK's Q3 Results Reflect MedSurg Strength & Rebound in Orthopaedics?
Stryker's Q3 results are expected to highlight MedSurg strength and solid robotics-led growth in Orthopaedics, partly offset by tariff headwinds.
Will RVTY Q3 Earnings Reflect Segmental Strength Amid Rising Demand?
RVTY's third-quarter results are likely to reflect strong performance in the Life Sciences segment. However, the Diagnostic segment is set to face challenges in China.
Paradice Investment Management Opens New $18 Million Position in Flowserve ( NYSE: FLS )
Paradice Investment Management LLC initiated a new position in Flowserve Corporation ( NYSE:FLS ) during the third quarter, acquiring 338,154 shares valued at an estimated $17.97 million as of 2025-09-30, according to an SEC filing dated October 20, 2025.Paradice Investment Management LLC ...
Paradice Investment Management Dumps $32 Million Worth of Openlane ( NYSE: KAR ) Stock: Should Investors Sell Too?
Paradice Investment Management LLC disclosed a significant reduction in its stake in Openlane ( NYSE:KAR ) , selling 1,187,526 shares during the quarter, an estimated $32.36 million trade based on the average price for the quarter, according to an October 20, 2025, SEC filing.
Paradice Investment Management Liquidates Its $20 Million Nomad Foods ( NYSE: NOMD ) Position: Is the Stock in Trouble?
Paradice Investment Management LLC exited its stake in Nomad Foods Limited ( NYSE:NOMD ) in the third quarter, selling 1,204,570 shares for an estimated $20.47 million during the quarter ended 2025-09-30, per October 20, 2025, SEC data.According to a filing with the United States Securities and ...
WST Q3 Earnings Preview: Can GLP-1 Momentum Outweigh Margin Pressure?
West Pharma's Q3 numbers hinge on robust GLP-1 and biologics demand, but labor constraints, tariffs, and plant shutdowns could test its margin resilience.
Globus Medical Schedules Third Quarter Earnings Release and Conference Call
AUDUBON, Pa., Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Globus Medical, Inc. ( NYSE:GMED ) , a leading musculoskeletal technology company, will announce its financial results for the third quarter ended September 30, 2025 after the market close on Thursday, November 6, 2025.
Globus Medical Launches ANTHEM™ Elbow Fracture System: A Comprehensive Plating Portfolio for Complex Elbow Trauma
AUDUBON, Pa., Oct. 14, 2025 ( GLOBE NEWSWIRE ) -- Globus Medical, Inc. ( NYSE: GMED ) , a leading musculoskeletal solutions company, has announced the launch of the ANTHEM™ Elbow Fracture System, a fully comprehensive plating portfolio designed to address a wide spectrum of elbow fractures.
Globus Medical Launches ANTHEM™ Elbow Fracture System: A Comprehensive Plating Portfolio for Complex Elbow Trauma - Globus Medical ( NYSE:GMED )
AUDUBON, Pa., Oct. 14, 2025 ( GLOBE NEWSWIRE ) -- Globus Medical, Inc. ( NYSE:GMED ) , a leading musculoskeletal solutions company, has announced the launch of the ANTHEM™ Elbow Fracture System, a fully comprehensive plating portfolio designed to address a wide spectrum of elbow fractures.
GMED vs. SONVY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical ( GMED Quick QuoteGMED - ) and SONOVA HOLDING ( SONVY Quick QuoteSONVY - ) . But which of these two stocks offers value investors a better bang for their buck right now?
Can ISRG Continue Its Strong Growth Amid Tariff & Rare Earth Woes?
ISRG's growth momentum faces pressure as tariffs and China's rare earth export curbs threaten margins and supply stability.
ZBH Receives PMDA Approval in Japan for iTaperloc Complete and iG7
Zimmer Biomet wins early PMDA approval in Japan for its iTaperloc Complete and iG7 Hip System with Iodine Technology.
Here's Why Globus Medical ( GMED ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Globus Medical ( GMED ) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Hold Onto Globus Medical Stock in Your Portfolio for Now?
GMED rides strong musculoskeletal demand and new launches, but faces currency headwinds and fierce competition.
Dentsply Sirona ( XRAY ) Q2 2025 Earnings Transcript
Image source: The Motley Fool.Thursday, August 7, 2025 at 8:30 a.m. ETChief Executive Officer - Daniel T. ScavillaContinue reading ...
Globus Medical, Inc. Secures Jury Verdict in Delaware Patent Litigation Against Life Spine, Inc.
AUDUBON, Pa., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Globus Medical, Inc. ( NYSE: GMED ) , a leading musculoskeletal technology company, announced that a Delaware jury has returned a verdict in favor of Globus in its patent infringement litigation against Life Spine, Inc.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
SP Platform's 88% Procedure Growth: The Next Frontier for ISRG?
Intuitive Surgical's SP platform posts 88% procedure growth in Q2, driven by a 112% surge in Korea and expanding adoption in colorectal and thoracic surgery.
Why Is Carlsmed Stock Gaining Monday? - Carlsmed ( NASDAQ:CARL )
CMS grants NTAP reimbursement of up to $21,125 for Carlsmed's spine implants. BofA forecasts 66% revenue growth in 2025, Buy rating with $16 target. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here → Carlsmed Inc.
ISRG's Ion Platform Procedure Grows 52%: Can This Trend Continue?
Intuitive Surgical's Ion platform saw Q2 procedures jump 52% to 35,000, expanding globally as utilization rises despite softer system placements.
Globus Medical Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
GMED posts strong Q2 with earnings and revenues, boosted by the Nevro acquisition and expanded margins.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Globus Medical ( GMED ) Q2 Revenue Up 18%
Globus Medical ( NYSE:GMED ) , a spinal and musculoskeletal medical device company, reported its Q2 2025 earnings on August 7, 2025. The main highlight was a jump in headline net income ( GAAP ) in Q2 2025, driven by unique, non-operational items such as a major acquisition gain and a one-time ...
Globus Medical ( GMED ) Beats Q2 Earnings and Revenue Estimates
Globus Medical (GMED) delivered earnings and revenue surprises of +13.16% and +0.49%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical Reports Second Quarter 2025 Results
AUDUBON, Pa., Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Globus Medical, Inc. ( NYSE: GMED ) , a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2025.
